Peptidoleukotriene release

"Peptidoleukotriene release" refers to the biosynthesis and secretion of cysteinyl leukotrienes (LTC₄, LTD₄, LTE₄), which are lipid mediators derived from arachidonic acid via the 5-lipoxygenase pathway. These molecules cause bronchoconstriction, increased vascular permeability, and mucus production, and play significant roles in asthma and allergic inflammation. Therapeutic agents target the receptors for these leukotrienes or their synthesis, not the release process itself[1][2][4]. In summary, "peptidoleukotriene release" is not a canonical drug target but a physiological process. The correct molecular targets involved are the cysteinyl leukotriene receptors (principally CysLT₁ receptor), which should be used for more precise, structured target mapping[1][2][4].

Other names

peptidoleukotrienescysteinyl leukotrienesCysLTsleukotriene C₄LTC₄leukotriene D₄LTD₄leukotriene E₄LTE₄